Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
$2.7M NIH grant evaluates TRE-515 with KRAS inhibitors in lung cancer, boosting Trethera’s FDA Fast Track pipeline with a novel approach to resistance
-
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...
-
EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...
-
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR BIORXIV QUI IDENTIFIE ET CARACTÉRISE UNE NOUVELLE MOLÉCULE SYNTHÉTIQUE, AB8939, COMME UN CANDIDAT MÉDICAMENT PROMETTEUR POUR LE...
-
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE...
-
BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
-
The global market for brain tumor therapeutics was valued at $2.5 billion in 2024 and is projected to reach $4.7 billion by the end of 2030.
-
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
-
The global fusion proteins market was valued at $32.4 billion in 2024 and is expected to reach $64.9 billion by the end of 2030 at a CAGR of 12.3%
-
Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells